Multicenter, phase II study of axitinib, a selective second-generation inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, in patients with metastatic melanoma.
about
Hepatocellular carcinoma: Will novel targeted drugs really impact the next future?Clinical efficacy and safety of bevacizumab monotherapy in patients with metastatic melanoma: predictive importance of induced early hypertensionPhase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma.Phase I Study of Axitinib in Combination with Cisplatin and Capecitabine in Patients with Previously Untreated Advanced Gastric Cancer.Vascular endothelial growth factor receptor tyrosine kinase inhibitors versus bevacizumab in metastatic colorectal cancer: A systematic review and meta-analysis.Treatment of NRAS-mutated advanced or metastatic melanoma: rationale, current trials and evidence to dateTherapy for metastatic melanoma: the past, present, and future.Axitinib in metastatic renal cell carcinoma: results of a pharmacokinetic and pharmacodynamic analysis.Gentian violet: a 19th century drug re-emerges in the 21st centuryPresurgical therapy with axitinib for advanced renal cell carcinoma: a case report.The combination of axitinib followed by paclitaxel/carboplatin yields extended survival in advanced BRAF wild-type melanoma: results of a clinical/correlative prospective phase II clinical trial.Axitinib increases the infiltration of immune cells and reduces the suppressive capacity of monocytic MDSCs in an intracranial mouse melanoma model.Combined vaccine+axitinib therapy yields superior antitumor efficacy in a murine melanoma model.Management of axitinib (AG-013736)-induced fatigue and thyroid dysfunction, and predictive biomarkers of axitinib exposure: results from phase I studies in Japanese patients.Phase I study of axitinib combined with paclitaxel, docetaxel or capecitabine in patients with advanced solid tumours.Two cases of gastrointestinal perforation after radiotherapy in patients receiving tyrosine kinase inhibitor for advanced renal cell carcinomaCytokines associated with toxicity in the treatment of recurrent glioblastoma with afliberceptPositron emission tomography imaging of vascular endothelial growth factor receptor expression with (61)Cu-labeled lysine-tagged VEGF121.Spheroid-plug model as a tool to study tumor development, angiogenesis, and heterogeneity in vivo.Efficacy and safety of axitinib versus sorafenib in metastatic renal cell carcinoma: subgroup analysis of Japanese patients from the global randomized Phase 3 AXIS trial.Tanycytic VEGF-A boosts blood-hypothalamus barrier plasticity and access of metabolic signals to the arcuate nucleus in response to fasting.Efficacy of combined axitinib with dacarbazine in a B16F1 melanoma xenograft modelIncidence and risk of hypertension with a novel multi-targeted kinase inhibitor axitinib in cancer patients: a systematic review and meta-analysis.Metastatic melanoma - a review of current and future drugsIntermittent dosing of axitinib combined with chemotherapy is supported by (18)FLT-PET in gastrointestinal tumours.BRAF and beyond: Tailoring strategies for the individual melanoma patientPharmacokinetic evaluation of axitinib.Advances in the management of melanoma: targeted therapy, immunotherapy and future directions.The risk of hand-foot skin reaction to axitinib, a novel VEGF inhibitor: a systematic review of literature and meta-analysis.Update on the targeted therapy of melanoma.Clinical pharmacology of axitinib.Inhibition of angiogenesis for the treatment of metastatic melanoma.Axitinib: a review of its safety and efficacy in the treatment of adults with advanced renal cell carcinoma.Non-BRAF targeted therapies for melanoma: protein kinase inhibitors in Phase II clinical trials.Angiogenesis, vasculogenic mimicry and vascular invasion in cutaneous malignant melanoma - implications for therapeutic strategies and targeted therapies.Non-BRAF-targeted therapy, immunotherapy, and combination therapy for melanoma.Mechanisms of tumour vascularization in cutaneous malignant melanoma: clinical implications.Axitinib safety in metastatic renal cell carcinoma: suggestions for daily clinical practice based on case studies.A new look at drugs targeting malignant melanoma--an application for mass spectrometry imaging.Receptor tyrosine kinase inhibitors: Are they real tumor killers?
P2860
Q26741201-91D854A3-C264-4D29-897C-45BC3CD06F3EQ28728389-192A49F7-2A4F-43C2-80CC-E7C65ADE7215Q33404877-DD2742CC-1E1C-4DD0-9C56-6CD5E3D7F9DFQ33420495-41E49A5A-5B6D-4D4E-A515-130DFAB73B91Q33424379-628F4EB0-5EAB-4D02-A2A0-F3C80585B76BQ33887664-CA6567CA-4C88-4305-AB28-2AA4A65601BCQ34183225-7EF5B3EF-1D01-43DA-ACF9-5274C1CBAC8BQ34245458-822B1400-3B49-410D-8CED-212F6C0CDCC9Q34377198-7B2732EC-F31F-4E78-A288-B92A338B451FQ35051078-AD82B5A8-BE70-4BC1-8BED-1D17FA86F53AQ35475284-C5DD4828-3D62-4AEF-9878-84148C243497Q35798966-A19CB7DD-6F63-4302-88A5-121985CBAB32Q35923178-17F3EA49-6246-4ED8-A567-CF2F2533C8A6Q35947278-EA5091BE-9D26-4037-BC61-3C0462E19677Q36387806-083EC463-30B7-4368-B6F7-0FD0F6CD37E2Q36392351-F9F6458F-8283-44A3-B7FC-1DA8AAF44C1BQ36712746-831AD047-E7C7-43CB-A362-AE254297DB47Q36746567-BE478F35-CCAD-4219-B676-6D082CB85F63Q36828773-AF12431A-8565-43C2-B126-DE2CA6855B91Q36876472-4F572C21-9F59-41C8-A304-4FFD062E2EA2Q36962238-44D9838D-9ACE-41A7-866A-C1954C7D9640Q37093432-4CEB2694-FF02-41D4-98BA-1BFCC653E135Q37161889-6F4DD66E-6B4A-4349-AA93-FB30F6220FE0Q37450733-43B94F53-8C8A-4722-A511-51658C6AA850Q37594384-34E1E4D6-68F1-4396-81FE-3E131291EF69Q37702515-A77DD745-29B1-4C95-96A8-E852C06CFE92Q37976135-9F0A7568-859D-4A78-BD3A-451E80685A0EQ38068205-A067D253-490D-4B48-98D3-3A07379D9622Q38076349-49EA4A30-1313-4EE8-A740-CE0D0CA8D26AQ38082713-2A148134-1AE3-4E8E-819D-DB57B6D7C6DDQ38107175-291C0393-5F28-4075-9F24-05A5E6BAE0CBQ38134302-89AE6C1B-1902-4EBC-92C6-4B6D9BBAF38FQ38163976-FCA1724C-7262-4E6E-898F-0A12AA2CE482Q38185688-03AADE6B-136B-400C-A119-65932C109CA5Q38186064-1CF01184-D45C-4536-BFC0-D2E579AD5EBEQ38195656-4A2D2751-B48F-4019-B414-D5A64BBC08C4Q38196881-309BEAA6-8E42-42FD-BA46-96FBA62C3448Q38196939-81159652-7D0D-4C64-A9F6-B6875DA65B6CQ38232032-4F315C6E-E1E1-4234-B010-95039414DB5EQ38365290-3582AD67-D9A0-4DF7-8B8F-7297797D0EA5
P2860
Multicenter, phase II study of axitinib, a selective second-generation inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, in patients with metastatic melanoma.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Multicenter, phase II study of ...... ents with metastatic melanoma.
@en
Multicenter, phase II study of ...... ents with metastatic melanoma.
@nl
type
label
Multicenter, phase II study of ...... ents with metastatic melanoma.
@en
Multicenter, phase II study of ...... ents with metastatic melanoma.
@nl
prefLabel
Multicenter, phase II study of ...... ents with metastatic melanoma.
@en
Multicenter, phase II study of ...... ents with metastatic melanoma.
@nl
P2093
P1476
Multicenter, phase II study of ...... ents with metastatic melanoma.
@en
P2093
Andreas G Niethammer
Brad Rosbrook
Charles K Brown
David McDermott
David R Shalinsky
Jean-Baptiste Meric
John Fruehauf
Jose Lutzky
Katherine F Liau
P304
P356
10.1158/1078-0432.CCR-11-0534
P407
P50
P577
2011-10-05T00:00:00Z